Immunotherapy for Orthotopic Murine Bladder Cancer Using Bacillus Calmette-Guerin Recombinant Protein Mpt-64

Journal of Urology

Volumn 177, Issue 2, 2007, Pages 738-742

  Yu, Dah Shyong ^a   Lee, Chi Feng ^a   Chang, Sun Yran ^a  

^a Uro Oncology Laboratory   (Taiwan)

Author keywords

bladder; bladder neoplasms; mice; Mycobacterium bovis; recombinant proteins

Indexed keywords

BCG VACCINE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 2; PROTEIN MPT 64; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLOOD LEVEL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; EXPRESSION VECTOR; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; MOLECULAR CLONING; MORTALITY; MOUSE; MYCOBACTERIUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR GROWTH; UROTHELIUM; WESTERN BLOTTING;

ANIMALS; ANTIGENS, BACTERIAL; FEMALE; IMMUNOTHERAPY; MICE; MICE, INBRED C3H; RECOMBINANT PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 33846123667     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.09.074     Document Type: Article

References (19)

1. Vegt P.D., Witjes J.A., Witjes W.P., Doesburg W.H., Debruyne F.M., and van der Meijden A.P. A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 153: (1995) 929
2. Morales A., Eidinger D., and Bruce A.W. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116 (1976) 180
3. Brandau S., and Bohle A. Therapy of bladder cancer with BCG: the mechanism behind a successful immunotherapy. Mod Asp Immunobiol 2 (2001) 37
4. Suzuki S., Shinohara N., Harabayashi T., Taniguchi A., Haga K., Sato S., et al. Complications of bacillus Calmette-Guerin therapy in superficial urothelial cancer: clinical analysis and implications. Int J Clin Oncol 7 (2002) 289
5. Zlotta A.R., Van Vooren J.P., Denis O., Drowart A., Daffe M., Lefevre P., et al. What are the immunologically active components of bacille Calmette-Guerin in therapy of superficial bladder cancer?. Int J Cancer 87 (2000) 844
6. Kuromatsu I., Matsuo K., Takamura S., Kim G., Takebe Y., Kawamura J., et al. Induction of effective antitumor immune responses in a mouse bladder tumor model by using DNA of an alpha antigen from mycobacteria. Cancer Gene Ther 8 (2001) 483
7. Morales A., Chin J.L., and Ramsey E.W. Mycobacterial cell wall extract for treatment of carcinoma in situ of the bladder. J Urol 166 (2001) 1633
8. Wilcke J.T., Jensen B.N., Ravn P., Andersen A.B., and Haslov K. Clinical evaluation of MPT-64 and MPT-59, two proteins secreted from Mycobacterium tuberculosis, for skin test reagents. Tuber Lung Dis 77 (1996) 250
9. Johnson P.D., Stuart R.L., Grayson M.L., Olden D., Clancy A., Ravn P., et al. Tuberculin-purified protein derivative-, MPT-64-, and ESAT-6-stimulated gamma interferon responses in medical students before and after Mycobacterium bovis BCG vaccination and in patients with tuberculosis. Clin Diagn Lab Immunol 6 (1999) 934
10. Lee C.F., Chang S.Y., Hsieh D.S., and Yu D.S. Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine. J Urol 171 (2004) 1343
11. Yu D.S., Lee C.F., Hsieh D.S., and Chang S.Y. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer. Urology 63 (2004) 596
12. Lee C.F., Chang S.Y., Hsieh D.S., and Yu D.S. Treatment of bladder carcinomas using recombinant BCG DNA vaccines and electroporative gene immunotherapy. Cancer Gene Ther 11 (2004) 194
13. Sylvester R.J., van der Meijden A.P., Witjes J.A., and Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005) 86
14. Alexandroff A.B., Jackson A.M., O'Donnell M.A., and James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet 353 (1999) 1689
15. DenOtter W., Dobrowolski Z., Bugajski A., Papla B., van Der Meijdenqq A.P., Koten J.W., et al. Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients. J Urol 159 (1998) 1183
16. Arnold J., de Boer E.C., O'Donnell M.A., Bohle A., and Brandau S. Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J Immunother 27 (2004) 116
17. Yamada H., Odonnell M., Matsumoto T., and Luo Y. Interferon-gamma up-regulates toll-like receptor 4 and cooperates with lipopolysaccharide to produce macrophage-derived chemokine and interferon-gamma inducible protein-10 in human bladder cancer cell line RT4. J Urol 174 (2005) 1119
18. Linn J.F., Black P., Derksen K., Rubben H., and Thuroff J.W. Keyhole limpet haemocyanin in experimental bladder cancer: literature review and own results. Eur Urol, suppl. 37 (2000) 34
19. Sanger C., Busche A., Bentien G., Spallek R., Jonas F., Bohle A., et al. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer. BMC Cancer 26: (2004) 86